Novel heterozygous mutation in NFKB2 in a patient with predominantly antibody deficiency

Publication: LymphoSign Journal
18 August 2023

Abstract

Background: The Nuclear Factor-kappa B (NF-kB) signaling pathway plays a critical role in regulating a wide range of cellular processes such as immune function, inflammation, and tumor regulation. There are two major pathways that play a role in NF-kB activation: the canonical NF-kB1 pathway and the non-canonical NF-kB2 pathway. Abnormalities in non-canonical NF-κB2 signaling are linked with significant impairments in the immune system, mainly B cell maturation, antibody production, as well as T helper and regulatory T cell function through its effect on germinal center regulation.
Methods: Our patient’s medical record was analyzed retrospectively, including her medical history, results from immune laboratory tests, and genetic analyses.
Results: We present a 16-year-old female with a history of chronic cough complicated with episodes of hemoptysis and diagnosed with bronchiectasis secondary to common variable immunodeficiency. Whole exome sequencing analysis revealed a novel heterozygous variant in the NFKB2 gene (NM_001077494.3), c.931C>T resulting in p.Arg311Cys.
Conclusion: The presence of NFKB2 mutations can lead to the development of early-onset common variable immunodeficiency.
Statement of Novelty: We have identified a novel variant in the NFKB2 gene associated with antibody deficiency.

Get full access to this article

View all available purchase options and get full access to this article.

REFERENCES

Aird A., Lagos M., Vargas-Hernández A., Posey J.E., Coban-Akdemir Z., Jhangiani S., Mace E.M., Reyes A., King A., Cavagnaro F., Forbes L.R., Chinn I.K., Lupski J.R., Orange J.S., and Poli M.C. (2019). Novel heterozygous mutation in NFKB2 is associated with early onset CVID and a functional defect in NK cells complicated by disseminated CMV infection and severe nephrotic syndrome. Front. Pediatr. 7: 303.
Bogaert D.J.A., De Bruyne M., Debacker V., Depuydt P., De Preter K., Bonroy C., Philippé J., Bordon V., Lambrecht B.N., Kerre T., Cerutti A., Vermaelen K.Y., Haerynck F., and Dullaers M. (2017). The immunophenotypic fingerprint of patients with primary antibody deficiencies is partially present in their asymptomatic first-degree relatives. Haematologica, 102(1): 192–202.
Bonilla F.A., Barlan I., Chapel H., Costa-Carvalho B.T., Cunningham-Rundles C., De La Morena M.T., Espinosa-Rosales F.J., Hammarström L., Nonoyama S., Quinti I., Routes J.M., Tang M.L.K., and Warnatz K. (2016). International consensus document (ICON): Common variable immunodeficiency disorders. J. Allergy Clin. Immunol. Pract. 4(1): 38–59.
Chen K., Coonrod E.M., Kumánovics A., Franks Z.F., Durtschi J.D., Margraf R.L., Wu W., Heikal N.M., Augustine N.H., Ridge P.G., Hill H.R., Jorde L.B., Weyrich A.S., Zimmerman G.A., Gundlapalli A.V., Bohnsack J.F., and Voelkerding K.V. (2013). Germline mutations in NFKB2 implicate the noncanonical NF-κB pathway in the pathogenesis of common variable immunodeficiency. Am. J. Hum. Genet. 93(5): 812–824.
De Leo P., Gazzurelli L., Baronio M., Montin D., Di Cesare S., Giancotta C., Licciardi F., Cancrini C., Aiuti A., Plebani A., Cicalese M.P., Lougaris V., and Fousteri G. (2020). NFKB2 regulates human Tfh and Tfr pool formation and germinal center potential. Clin Immunol. 210: 108309.
De Valles-Ibáñez G., Esteve-Solé A., Piquer M., González-Navarro E.A., Hernandez-Rodriguez J., Laayouni H., González-Roca E., Plaza-Martin A.M., Deyà-Martínez Á., Martín-Nalda A., Martínez-Gallo M., García-Prat M., Del Pino-Molina L., Cuscó I., Codina-Solà M., Batlle-Masó L., Solís-Moruno M., Marquès-Bonet T., Bosch E., López-Granados E., Aróstegui J.I., Soler-Palacín P., Colobran R., Yagüe J., Alsina L., Juan M., Casals F., and Casals F. (2018). Evaluating the genetics of common variable immunodeficiency: Monogenetic model and beyond. Front. Immunol. 9: 636.
Gereige J.D. and Maglione P.J. (2019). Current understanding and recent developments in common variable immunodeficiency associated autoimmunity. Front. Immunol. 10: 2753.
Klemann C., Camacho-Ordonez N., Yang L., Eskandarian Z., Rojas-Restrepo J.L., Frede N., Bulashevska A., Heeg M., Al-Ddafari M.S., Premm J., Seidl M., Ammann S., Sherkat R., Radhakrishnan N., Warnatz K., Unger S., Kobbe R., Hüfner A., Leahy T.R., Ip W., Burns S.O., Fliegauf M., and Grimbacher B. (2019). Clinical and immunological phenotype of patients with primary immunodeficiency due to damaging mutations in NFKB2. Front. Immunol. 10: 297.
Kotlinowski J., Bukowska-Strakova K., Koppolu A., Kosińska J., Pydyn N., Stawinski P., Wilamowski M., Nowak W., Józkowicz A., Baran J., Płoski R., and Jura J. (2019). A novel monoallelic nonsense mutation in the NFKB2 gene does not cause a clinical manifestation. Front. Genet. 10: 140.
Kuehn H.S., Niemela J.E., Sreedhara K., Stoddard J.L., Grossman J., Wysocki C.A., De La Morena M.T., Garofalo M., Inlora J., Snyder M.P., Lewis D.B., Stratakis C.A., Fleisher T.A., and Rosenzweig S.D. (2017). Novel nonsense gain-of-function NFKB2 mutations associated with a combined immunodeficiency phenotype. Blood, 130(13): 1553–1564.
Lee C.E., Fulcher D.A., Whittle B., Chand R., Fewings N., Field M., Andrews D., Goodnow C.C., and Cook M.C. (2014). Autosomal-dominant B-cell deficiency with alopecia due to a mutation in NFKB2 that results in nonprocessable p100. Blood, 124(19): 2964–2972.
Lindsley A.W., Qian Y., Valencia C.A., Shah K., Zhang K., and Assa’ad A. (2014). Combined immune deficiency in a patient with a novel NFKB2 mutation. J. Clin. Immunol. 34(8): 910–915.
Lorenzini, T., Fliegauf, M., Klammer, N., Frede, N., Proietti, M., Bulashevska, A., Camacho-Ordonez, N., Varjosalo, M., Kinnunen, M., de Vries, E., van der Meer, J.W.M., Ameratunga, R., Roifman, C.M., Schejter, Y.D., Kobbe, R., Hautala, T., Atschekzei, F., Schmidt, R.E., Schröder, C., Stepensky, P., Shadur, B., Pedroza, L.A., Flier, M.V.D., Martínez-Gallo, M., Gonzalez-Granado, L.I., Allende, L.M., Shcherbina, A., Kuzmenko, N., Zakharova, V., Neves, J.F., Svec, P., Fischer, U., Ip, W., Bartsch, O., Barış, S., Klein, C., Geha, R., Chou, J., Alosaimi, M., Weintraub, L., Boztug, K., Hirschmugl, T., Vilela, M.M.D.S., Holzinger, D., Seidl, M., Lougaris, V., Plebani, A., Alsina, L., Piquer-Gibert, M., Deyà-Martínez, A., Slade, C.A., Aghamohammadi, A., Abolhassani, H., Hammarström, L., Kuismin, O., Helminen, M., Allen, H.L., Thaventhiran, J.E., Freeman, A.F., Cook, M., Bakhtiar, S., Christiansen, M., Cunningham-Rundles, C., Patel, N.C., Rae, W., Niehues, T., Brauer, N., Syrjänen, J., Seppänen, M.R.J., Burns, S.O., Tuijnenburg, P., Kuijpers, T.W., on behalf of NIHR BioResource, Warnatz, K., Grimbacher, B., and NIHR BioResource NIHR BioResource. (2020). Characterization of the clinical and immunologic phenotype and management of 157 individuals with 56 distinct heterozygous NFKB1 mutations. J. Allergy Clin. Immunol. 146(4): 901–911.
Rojas-Restrepo J., Caballero-Oteyza A., Huebscher K., Haberstroh H., Fliegauf M., Keller B., Kobbe R., Warnatz K., Ehl S., Proietti M., and Grimbacher B. (2021). Establishing the molecular diagnoses in a cohort of 291 patients with predominantly antibody deficiency by targeted next-generation sequencing: Experience from a monocentric study. Front. Immunol. 12: 786516.
Shi C., Wang F., Tong A., Zhang X.-Q., Song H.-M., Liu Z.-Y., Lyu W., Liu Y.-H., and Xia W.-B. (2016). NFKB2 mutation in common variable immunodeficiency and isolated adrenocorticotropic hormone deficiency: A case report and review of literature. Medicine, 95(40): e5081.
Sun S.-C. (2017). The non-canonical NF-κB pathway in immunity and inflammation. Nat. Rev. Immunol., 17(9): 545–558.
Wirasinha R.C., Davies A.R., Srivastava M., Sheridan J.M., Sng X.Y.X., Delmonte O.M., Dobbs K., Loh K.L., Miosge L.A., Lee C.E., Chand R., Chan A., Yap J.Y., Keller M.D., Chen K., Rossjohn J., La Gruta N.L., Vinuesa C.G., Reid H.H., Lionakis M.S., Notarangelo L.D., Gray D.H.D., Goodnow C.C., Cook M.C., and Daley S.R. (2021). Nfkb2 variants reveal a p100-degradation threshold that defines autoimmune susceptibility. J. Exp. Med. 218(2): e20200476.

Information & Authors

Information

Published In

cover image LymphoSign Journal
LymphoSign Journal
Volume 10Number 2June 2023
Pages: 30 - 35

History

Received: 7 June 2023
Accepted: 22 June 2023
Accepted manuscript online: 23 June 2023
Version of record online: 18 August 2023

Authors

Affiliations

Azhar Al Shaqaq
Division of Immunology & Allergy, Department of Pediatrics, Hospital for Sick Children and University of Toronto, Toronto, ON
Amarilla B. Mandola [email protected]
Edmund and Lilly Safra Children’s Hospital, Sheba Medical Centre, Pediatric Department A and Immunology Service, Tel Hashomer, Israel; Clinical Immunology, Angioedema and Allergy Unit, Center for Autoimmune Diseases, Sheba Medical Center, Tel Hashomer, Israel; The Sackler School of Medicine, Tel-Aviv University, Tel-Aviv, Israel

Metrics & Citations

Metrics

Other Metrics

Citations

Cite As

Export Citations

If you have the appropriate software installed, you can download article citation data to the citation manager of your choice. Simply select your manager software from the list below and click Download.

There are no citations for this item

View Options

Get Access

Login options

Check if you access through your login credentials or your institution to get full access on this article.

Subscribe

Click on the button below to subscribe to LymphoSign Journal

Purchase options

Purchase this article to get full access to it.

Restore your content access

Enter your email address to restore your content access:

Note: This functionality works only for purchases done as a guest. If you already have an account, log in to access the content to which you are entitled.

View options

PDF

View PDF

Full Text

View Full Text

Media

Media

Other

Tables

Share Options

Share

Share the article link

Share on social media